Vaccines are mainly used as preventive medicine for infectious diseases worldwide; however, recent studies have indicated the potential of therapeutic vaccines for Alzheimer's disease or hypertension. Increasing the effectiveness of drug adherence interventions may have a great impact on the health of the population, because it is reported that approximately 50% may not take medications among patients with chronic illness. This poor adherence to medication leads to increased morbidity and death. If the improvement of drug compliance has been achieved with vaccines in hypertensive patients, it may assist better control of blood pressure, leading to reduced complications. Recently, we have attempted to develop a therapeutic vaccine against hypertension.Design and Method: :
Angiotensin II –KLH conjugate was used with adjuvant for Angiotensin II vaccine in mice. DNA vaccines have also been designed via a similar strategy using a plasmid vector encoding a hepatitis B core (HBc)-angiotensin II fusion protein. The immunogenic molecule (i.e., HBc) is used to provide an antigen that supports the activation of helper T-cells in this DNA vaccine system for Spontaneous Hypertensive Rat (SHR).Results:
Angiotensin II vaccine successfully induced anti-angiotensin II antibody titer in a dose dependent manner. The vaccine-induced anti-angiotensin II antibodies can efficiently ameliorated angiotensin II-induced high blood pressure and perivascular fibrosis in mice. Similar results were obtained in SHR.Conclusions:
The study may eventually provide a novel alternative to treat high blood pressure in people, who would not need to take a pill every day. The potential of a vaccine for hypertension offers an innovative treatment that could be very effective for the control of non-compliance which is one of the major problems in the management of hypertensive patients.